Compass Ion Advisors LLC Purchases 10,363 Shares of Incyte Co. (NASDAQ:INCY)

Compass Ion Advisors LLC raised its position in Incyte Co. (NASDAQ:INCY) by 293.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,894 shares of the biopharmaceutical company’s stock after buying an additional 10,363 shares during the quarter. Compass Ion Advisors LLC’s holdings in Incyte were worth $960,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in INCY. GSA Capital Partners LLP raised its stake in Incyte by 26.5% in the 3rd quarter. GSA Capital Partners LLP now owns 6,453 shares of the biopharmaceutical company’s stock valued at $427,000 after acquiring an additional 1,351 shares during the period. CIBC Asset Management Inc increased its stake in shares of Incyte by 2.9% in the third quarter. CIBC Asset Management Inc now owns 25,303 shares of the biopharmaceutical company’s stock worth $1,673,000 after purchasing an additional 723 shares in the last quarter. Swiss National Bank raised its position in shares of Incyte by 0.9% in the third quarter. Swiss National Bank now owns 483,274 shares of the biopharmaceutical company’s stock valued at $31,944,000 after purchasing an additional 4,500 shares during the period. Meeder Asset Management Inc. purchased a new stake in shares of Incyte during the 3rd quarter valued at approximately $186,000. Finally, Banque Cantonale Vaudoise boosted its holdings in Incyte by 336.1% in the 3rd quarter. Banque Cantonale Vaudoise now owns 8,730 shares of the biopharmaceutical company’s stock worth $577,000 after buying an additional 6,728 shares during the period. Hedge funds and other institutional investors own 96.97% of the company’s stock.

Incyte Trading Down 3.2 %

NASDAQ INCY opened at $60.00 on Wednesday. The company has a quick ratio of 1.94, a current ratio of 1.97 and a debt-to-equity ratio of 0.01. The stock’s 50-day simple moving average is $71.29 and its two-hundred day simple moving average is $70.27. Incyte Co. has a twelve month low of $50.35 and a twelve month high of $83.95. The company has a market capitalization of $11.61 billion, a price-to-earnings ratio of 222.23, a PEG ratio of 0.41 and a beta of 0.76.

Incyte (NASDAQ:INCY) last announced its quarterly earnings data on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.48). Incyte had a net margin of 0.77% and a return on equity of 0.05%. Research analysts forecast that Incyte Co. will post 4.86 EPS for the current fiscal year.

Insider Transactions at Incyte

In other Incyte news, EVP Sheila A. Denton sold 599 shares of the business’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $69.99, for a total value of $41,924.01. Following the completion of the sale, the executive vice president now directly owns 25,848 shares of the company’s stock, valued at $1,809,101.52. The trade was a 2.26 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Barry P. Flannelly sold 19,807 shares of the firm’s stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $67.69, for a total value of $1,340,735.83. Following the transaction, the executive vice president now directly owns 33,567 shares in the company, valued at $2,272,150.23. This trade represents a 37.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 46,827 shares of company stock worth $3,322,618. 17.60% of the stock is currently owned by insiders.

Analyst Ratings Changes

INCY has been the topic of a number of analyst reports. UBS Group initiated coverage on shares of Incyte in a report on Tuesday, December 17th. They set a “neutral” rating and a $77.00 target price on the stock. StockNews.com lowered Incyte from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 12th. JMP Securities reissued a “market perform” rating on shares of Incyte in a report on Tuesday, February 11th. Guggenheim cut Incyte from a “buy” rating to a “neutral” rating and set a $92.00 price target on the stock. in a research report on Tuesday. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of Incyte in a research report on Friday, January 10th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $75.13.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.